Intravenous vs Oral Lansoprazole on Gastric Acid Secretion in Subjects With Erosive Esophagitis [clinicaltrials:NCT00175045]
Intravenous vs Oral Lansoprazole on Gastric Acid Secretion in Subjects With Erosive Esophagitis [clinicaltrials:NCT00175045]
Bio2RDF identifier
NCT00175045
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00175045
identifiers.org URI
actual enrollment [clinicaltrials_vocabulary:actual-enrollment]
arm group [clinicaltrials_vocabulary:arm-group]
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
The purpose of this stu ...... th erosive
esophagitis.
brief title [clinicaltrials_vocabulary:brief-title]
Intravenous vs Oral Lansoprazo ...... jects With Erosive Esophagitis
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
completion date [clinicaltrials_vocabulary:completion-date]
2003-10-01T00:00:00Z
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
detailed description [clinicaltrials_vocabulary:detailed-description]
Phase 2, open label, mu ...... or= 2)diagnosed by endoscopy.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
2005-09-12T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]
is section 801 [clinicaltrials_vocabulary:is-section-801]
keyword [clinicaltrials_vocabulary:keyword]
Esophagitis
Intravenous
Lansoprazole
gastric acid secretion
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2010-07-20T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
link [clinicaltrials_vocabulary:link]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00175045
number of arms [clinicaltrials_vocabulary:number-of-arms]
official title [clinicaltrials_vocabulary:official-title]
A Phase 2, Open-Label Multicen ...... jects With Erosive Esophagitis
org study id [clinicaltrials_vocabulary:org-study-id]
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
primary completion date [clinicaltrials_vocabulary:primary-completion-date]
2003-10-01T00:00:00Z
responsible party [clinicaltrials_vocabulary:responsible-party]
secondary id [clinicaltrials_vocabulary:secondary-id]
U1111-1114-2148
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
2003-06-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2010-07-01T00:00:00Z
identifier
clinicaltrials:NCT00175045
title
Intravenous vs Oral Lansoprazo ...... jects With Erosive Esophagitis
@en
type
label
Intravenous vs Oral Lansoprazo ...... s [clinicaltrials:NCT00175045]
@en